Normal Hepatic Function Clinical Trials

NCT ID: NCT02871570 Completed - Clinical trials for Moderate Hepatic Impairment

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Start date: September 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the effect of hepatic impairment on rivipansel PK and safety.

NCT ID: NCT02611505 Completed - Hepatic Impairment Clinical Trials

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

Start date: November 30, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of intranasally administered esketamine in both participants with varying stages of hepatic impairment and healthy participants.

NCT ID: NCT02388620 Completed - Clinical trials for Impaired Hepatic Function

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

Start date: March 25, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics (PK), safety and tolerability of a single oral dose of LEE011 in subjects with varying degrees of impaired hepatic function (based on Child-Pugh classification) as compared to demographically-matched control subjects with normal hepatic function.

NCT ID: NCT02138162 Completed - Clinical trials for Severe Hepatic Impairment

A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

Start date: August 2013
Phase: Phase 1
Study type: Interventional

The influence of severely diminished liver function on the metabolism, safety, and tolerability of a single oral dose of enzalutamide in a group of 8 men. The results are compared to the data gained from 8 age- and BMI-matched men with normal liver function.

NCT ID: NCT01950481 Completed - Clinical trials for Impaired Hepatic Function

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

Start date: January 2014
Phase: Phase 1
Study type: Interventional

Pharmacokinetics and safety of 750 mg of LDK378 given once orally in subjects with impaired hepatic function and healthy subjects with normal hepatic function.

NCT ID: NCT01764776 Completed - Clinical trials for Impaired Hepatic Function

Effect of Hepatic Impairment on LDE225..

Start date: March 2013
Phase: Phase 1
Study type: Interventional

This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects with impaired hepatic function and healthy subjects with normal hepatic function.